Biofrontera Inc. (NASDAQ:BFRI) Short Interest Update

Biofrontera Inc. (NASDAQ:BFRI) saw a large decline in short interest in the month of August. As of August 14th, there was short interest totaling 32,907 shares, a decline of 46.1% from the July 30th total of 61,079 shares. Based on an average daily trading volume, of 464,283 shares, the short-interest ratio is currently 0.1 days. Currently, 0.2% of the company’s shares are sold short.

Biofrontera Stock Up 6.7%

BFRI traded up $0.10 during trading on Friday, reaching $1.59. The company had a trading volume of 807,575 shares, compared to its average volume of 551,162. The company has a debt-to-equity ratio of 0.78, a current ratio of 1.18 and a quick ratio of 1.08. Biofrontera has a 12 month low of $0.55 and a 12 month high of $1.61. The business’s fifty day moving average price is $1.19 and its 200 day moving average price is $1.02. The company has a market cap of $23.61 million, a P/E ratio of -3.53 and a beta of 0.78.

Biofrontera (NASDAQ:BFRI) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.05. The company had revenue of $12.00 million during the quarter, compared to the consensus estimate of $9.50 million. Biofrontera had a negative net margin of 13.78% and a negative return on equity of 145.81%. Equities analysts anticipate that Biofrontera will post -0.6 EPS for the current year.

Hedge Funds Weigh In On Biofrontera

A hedge fund recently raised its position in Biofrontera stock. Rosalind Advisors Inc. grew its holdings in Biofrontera Inc. (NASDAQ:BFRI) by 51.5% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 976,448 shares of the company’s stock after purchasing an additional 332,055 shares during the period. Biofrontera comprises approximately 0.3% of Rosalind Advisors Inc.’s investment portfolio, making the stock its 27th biggest holding. Rosalind Advisors Inc. owned approximately 9.63% of Biofrontera worth $695,000 at the end of the most recent quarter. 10.08% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the stock. Weiss Ratings upgraded shares of Biofrontera from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, July 15th. Zacks Research upgraded Biofrontera from a “strong sell” rating to a “hold” rating in a report on Monday, August 3rd. Finally, Wall Street Zen upgraded Biofrontera to a “hold” rating in a report on Saturday, July 18th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Biofrontera presently has a consensus rating of “Hold”.

About Biofrontera

Biofrontera AG is a specialty biopharmaceutical company focused on the research, development and commercialization of products for dermatological applications. The company’s core expertise lies in photodynamic therapy (PDT), a treatment modality that uses a photosensitizing agent activated by a specific light source to target diseased skin cells while sparing surrounding healthy tissue.

The flagship product in Biofrontera’s portfolio is Ameluz (aminolevulinic acid hydrochloride 10 % gel), which has received marketing approval in the European Union for treatment of actinic keratosis and basal cell carcinoma, and in the United States for actinic keratosis.